Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Publication

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

Journal Paper/Review - Aug 19, 2020

Ludwig Heinz, Einsele Hermann, Delforge Michel, Caers Jo, Weisel Katja, Jackson Graham, Garderet Laurent, Engelhardt Monika, van de Donk Niels, Leleu Xavier, Goldschmidt Hartmut, Beksac Meral, Nijhof Inger, Abildgaard Niels, Bringhen Sara, Mateos Maria-Victoria, Mohty Mohamad, Boccadoro Mario, Moreau Philippe, San-Miguel Jesus, Cavo Michele, Pawlyn Charlotte, Zweegman Sonja, Facon Thierry, Driessen Christoph, Hájek Roman, Dimopoulos Melitios A, Gay Francesca, Avet-Loiseau Hervé, Terpos Evangelos, Zojer Niklas, Sonneveld Pieter

Citation

Ludwig H, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Mateos M, Mohty M, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hájek R, Dimopoulos M, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2020; 35:31-44.

Type

Journal Paper/Review (English)

Journal

Leukemia 2020; 35

Publication Date

Aug 19, 2020

Issn Electronic

1476-5551

Pages

31-44

Brief description/objective

Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.